Skip to main content
. 2020 Sep 3;12(9):2500. doi: 10.3390/cancers12092500

Figure 5.

Figure 5

Enhanced anti-tumor efficacy of abemaciclib combined with BYL719 in colon cancer xenografts. (A) Athymic nude mice bearing SNU-C4 xenografts were administered with vehicle, abemaciclib (25 or 50 mg/kg/day) alone, BYL719 (15 or 30 mg/kg/day) alone, or the combination of abemaciclib and BYL719. (B) Body weight and survival were evaluated every seven days. (C) The overall anti-tumor efficacy of drugs was measured by tumor volume every seven days. Error bars represent the standard error of the mean. (D) Formalin-fixed paraffin-embedded tumor sections were stained with H&E and for p-AKT S473, Ki67, and TUNEL. Scale bar: 300 μm.